Moderna topped Wall Street sales expectations and reported a lower-than-expected second-quarter loss on Friday, driven by robust Spring COVID booster demand and aggressive cost cuts. Moderna said 40% to 50% of that revenue will be recognized in the third quarter of 2025,

Moderna to cut 10% of global workforce by 2025 as COVID vaccine sales drop and restructuring efforts accelerate.

Moderna Inc. is cutting about 10% of its workforce, part of an effort by the struggling biotech company to reduce spending as sales of its Covid vaccine decline.